Daily Cardiology Research Analysis
Three studies reshape cardiovascular thinking this week: HFpEF appears almost universally characterized by central adiposity where waist-to-height ratio outperforms BMI; after acute MI, new-onset heart failure is more common than recurrent MI, even in patients with normal EF; and CCN5 emerges as a dual-acting anti-restenosis factor that inhibits VSMC proliferation while accelerating endothelial repair, with efficacy shown in a porcine stent model.
Summary
Three studies reshape cardiovascular thinking this week: HFpEF appears almost universally characterized by central adiposity where waist-to-height ratio outperforms BMI; after acute MI, new-onset heart failure is more common than recurrent MI, even in patients with normal EF; and CCN5 emerges as a dual-acting anti-restenosis factor that inhibits VSMC proliferation while accelerating endothelial repair, with efficacy shown in a porcine stent model.
Research Themes
- Central adiposity as a core HFpEF phenotype and risk marker
- Incident heart failure after MI vs recurrent MI risk prioritization
- Translational anti-restenosis biology (CCN5) enabling pro-healing stents
Selected Articles
1. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
In PARAGON-HF, 96% of HFpEF patients had central adiposity (WHtR ≥0.5) and WHtR, more than BMI, showed a linear association with adverse HF outcomes without an obesity survival paradox. WHtR identified more high-risk patients and challenges BMI reliance in HFpEF characterization and risk stratification.
Impact: This analysis reframes HFpEF as a central adiposity–driven syndrome and elevates WHtR as a pragmatic, superior risk metric over BMI, with broad implications for phenotyping and management.
Clinical Implications: In HFpEF clinics, incorporate waist-to-height ratio to refine risk stratification and counseling; consider targeting central adiposity in lifestyle and therapeutic strategies rather than BMI alone.
Key Findings
- Central adiposity (WHtR ≥0.5) was present in 96% of HFpEF patients; 37% of non-obese (BMI <30 kg/m2) had marked central adiposity (WHtR ≥0.6).
- WHtR showed a linear association with total HF hospitalizations and identified a larger high-risk fraction than BMI.
- The obesity survival paradox seen with BMI in unadjusted analyses was not observed with WHtR.
Methodological Strengths
- Large randomized trial dataset (n=4796) with standardized adjudication of outcomes.
- Direct comparison of BMI vs WHtR with consistent modeling across outcomes.
Limitations
- Post hoc analysis; potential residual confounding and selection inherent to trial enrollment.
- Anthropometric measures limited to BMI and WHtR; no imaging-based adiposity quantification.
Future Directions: Prospective validation of WHtR-guided risk stratification and trials targeting central adiposity (e.g., exercise, nutrition, pharmacologic weight reduction) in HFpEF.
BACKGROUND AND AIMS: An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposity-the waist-to-height ratio (WHtR)-focuses on body fat content and distribution; is not distorted by bone or muscle mass, sex, or ethnicity; and may be particularly relevant in HFpEF. METHODS: The PARAGON-HF trial randomized 4796 patients with heart failure (HF) and ejection fraction ≥45% to valsartan or sacubitril/valsartan. The current work characterizes the association of BMI and WHtR with clinical features, outcomes, and the response to neprilysin inhibition. RESULTS: About half (49%) of the participants were considered obese by BMI (≥30 kg/m2), but nearly every patient (96%) had central adiposity (WHtR ≥.5). Among patients who were not obese (BMI <30 kg/m2), 860 (37%) had marked central adiposity (WHtR ≥.6). Higher BMI and WHtR were both associated with higher risk of total HF hospitalizations, but as compared with BMI, WHtR was linearly associated with HF outcomes and identified a higher proportion of patients who had a particularly elevated risk (i.e. 30% or greater). An obesity-survival paradox (i.e. improved outcomes in those with greater adiposity) was apparent with BMI in unadjusted analyses, but it was not observed with WHtR. Although neprilysin inhibition appeared to have greater effects on HF outcomes in patients with higher BMI and WHtR, analyses of interaction with obesity metrics did not show significant heterogeneity across the range of values for adiposity. CONCLUSIONS: In PARAGON-HF, in contrast with BMI, nearly every patient with HFpEF had central adiposity (as assessed by WHtR), and the risks of adverse HF events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that-rather than obesity-related HFpEF being regarded as a select HFpEF subgroup-central adiposity is a ubiquitous feature of HFpEF.
2. CCN5 suppresses injury-induced vascular restenosis by inhibiting smooth muscle cell proliferation and facilitating endothelial repair via thymosin β4 and Cd9 pathway.
CCN5 emerged as a dual-acting regulator of restenosis: it restrains VSMC proliferation and accelerates endothelial repair via Tβ4/Ac-SDKP and Cd9 pathways. A CCN5 recombinant protein–coated stent increased endothelial coverage and reduced neointimal formation in a porcine model, highlighting a pro-healing anti-ISR strategy.
Impact: Provides mechanistic and translational evidence for a bioactive, pro-healing stent coating that could reduce ISR while promoting endothelialization—addressing a core limitation of current drug-eluting stents.
Clinical Implications: If translated clinically, CCN5-based coatings could lower ISR without impairing healing, potentially shortening DAPT needs and improving long-term patency after PCI.
Key Findings
- Plasma CCN5 levels were reduced in ISR patients and correlated with restenosis severity; VSMC CCN5 was downregulated in injured/stented segments while regenerating ECs showed increased CCN5.
- Cell-specific CCN5 deletion aggravated neointimal hyperplasia; gain-of-function attenuated it.
- Mechanistically, EC-CCN5 interacted with thymosin β4 leading to Ac-SDKP–mediated repair and engaged Cd9 to promote endothelial repair; CCN5rp-coated stents increased EC coverage and reduced neointimal growth in porcine arteries.
Methodological Strengths
- Multi-system validation across human plasma, porcine coronary stenting, and mouse vascular injury models.
- Mechanistic depth via scRNA-seq, proteomics, and cell-specific genetic manipulation.
Limitations
- Preclinical nature; clinical efficacy and safety of CCN5-coated stents require human trials.
- Quantitative sample sizes per experiment are not detailed in the abstract.
Future Directions: First-in-human studies of CCN5-coated stents focusing on endothelialization, ISR, thrombosis, and DAPT duration; exploration of CCN5 agonism or delivery systems.
BACKGROUND AND AIMS: Members of the CCN matricellular protein family are crucial in various biological processes. This study aimed to characterize vascular cell-specific effects of CCN5 on neointimal formation and its role in preventing in-stent restenosis (ISR) after percutaneous coronary intervention (PCI). METHODS: Stent-implanted porcine coronary artery RNA-seq and mouse injury-induced femoral artery neointima single-cell RNA sequencing were performed. Plasma CCN5 levels were measured by enzyme-linked immunosorbent assay. Endothelial cell (EC)- and vascular smooth muscle cell (VSMC)-specific CCN5 loss-of-function and gain-of-function mice were generated. Mass spectrometry and co-immunoprecipitation were conducted to identify CCN5 interacting proteins. Additionally, CCN5 recombinant protein (CCN5rp)-coated stents were deployed to evaluate its anti-ISR effects in a porcine model. RESULTS: Plasma CCN5 levels were significantly reduced and correlated closely with the degree of restenosis in ISR patients. CCN5 expression was significantly decreased in VSMCs of stent-implanted porcine coronary segments and injured mouse femoral arteries, especially in synthetic VSMCs. In contrast, elevated CCN5 expression was observed in regenerating ECs of injured vessels. Endothelial cell- and VSMC-specific CCN5 deletion mice exhibited exacerbation of injury-induced neointimal hyperplasia, while CCN5 gain-of-function alleviated neointimal formation. Mechanistic studies identified thymosin β4 (Tβ4) as a CCN5 interacting protein in ECs and EC-CCN5 promoted injury repair through Tβ4 cleavage product Ac-SDKP. Also, CCN5rp promoted EC repair to suppress neointimal hyperplasia via interaction with Cd9 extracellular domain. Moreover, implantation with CCN5rp-coated stent significantly increased stent strut coverage with ECs, which suppressed neointimal formation and ultimately alleviated ISR. CONCLUSIONS: CCN5 exerts a dual protective effect on ISR by inhibiting VSMC proliferation and facilitating EC repair. CCN5rp-coated stent might be promising in the prevention of ISR after PCI.
3. Incident heart failure and recurrent coronary events following acute myocardial infarction.
Among 6,804 MI patients, incident HF exceeded recurrent MI, including in those with EF >50% and no HF at discharge. New-onset HF conferred higher risks of death and hospitalization regardless of EF, reframing post-MI priorities toward HF prevention and early detection.
Impact: Shifts post-MI care focus by demonstrating higher short-term burden of incident HF than recurrent MI, even with preserved EF, highlighting the need for systematic HF surveillance and prevention.
Clinical Implications: Implement structured post-MI HF surveillance (biomarkers, echocardiography, symptom checks), aggressive risk-factor and GDMT optimization, and early referral to HF programs even for preserved EF patients.
Key Findings
- Landmark 1-year recurrent MI occurred in 3.8%, while 23.8% developed incident HF within 3 months among those without prior HF.
- Among patients with EF >50% and no HF at discharge (n=2179), 11.8% developed HF and 3.5% had recurrent MI within 1 year.
- Incident HF was associated with higher mortality and hospitalization risk irrespective of EF (all P<.001).
Methodological Strengths
- Large multi-hospital cohort with contemporary management and landmark analysis to reduce immortal time bias.
- Comprehensive outcomes including EF-stratified HF incidence and rehospitalization.
Limitations
- Observational design with potential residual confounding and misclassification.
- Single health system; generalizability may vary across regions and care models.
Future Directions: Trial and implementation studies testing structured HF surveillance and preventive strategies post-MI, including for preserved EF populations.
BACKGROUND AND AIMS: Recurrent myocardial infarction (MI) and incident heart failure (HF) are major post-MI complications. Herein, contemporary post-MI risks for recurrent MI and HF are described. METHODS: A total of 6804 patients with a primary discharge diagnosis of MI at 28 Baylor Scott & White Health hospitals (January 2015 to December 2021) were studied. Patient characteristics, treatment, and outcomes, including incident HF, recurrent MI, all-cause death, and all-cause and cardiovascular rehospitalizations, were assessed. Landmark approach anchored at 3 months post-discharge was used to assess 1-year outcomes. RESULTS: Median age was 69 years, 59.7% were male, and 76.7% had non-ST-elevation MI. Comorbidities included hypertension (89%), dyslipidaemia (87%), Type 2 diabetes (48%), and chronic kidney disease (34%); 17% had a history of MI and 23% of HF; 63% underwent percutaneous/surgical revascularization. In landmark-anchored 1-year outcomes (N = 6210), 413 (6.7%) patients died, 1730 (27.9%) had all-cause and 735 (11.8%) cardiovascular hospitalizations, 234 (3.8%) had recurrent MI. Of patients without history of HF, 1160 (23.8%) developed incident HF [42.2%, 26.7%, and 31.1% with ejection fraction (EF) < 40%, 41-49%, and >50%, respectively) within 3 months of discharge. Patients who developed HF had higher risk of death and hospitalizations (all P < .001), irrespective of EF. Of 2179 patients with EF > 50% without prevalent HF or HF during index hospitalization, 257 (11.8%) developed HF and 77 (3.5%) recurrent MI within 1 year. CONCLUSIONS: In a contemporary post-MI cohort, the risk for incident HF was greater than recurrent MI, even among those with normal EF and no HF at discharge.